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Administration of human recombinant erythropoietin (EPO)
at time of acute ischemic renal injury (IRI) inhibits apoptosis,
enhances tubular epithelial regeneration, and promotes renal
functional recovery. The present study aimed to determine
whether darbepoetin-alfa (DPO) exhibits comparable
renoprotection to that afforded by EPO, whether pro or
antiapoptotic Bcl-2 proteins are involved, and whether
delayed administration of EPO or DPO 6 h following IRI
ameliorates renal dysfunction. The model of IRI involved
bilateral renal artery occlusion for 45 min in rats (N¼ 4 per
group), followed by reperfusion for 1–7 days. Controls were
sham-operated. Rats were treated at time of ischemia or
sham operation (T0), or post-treated (6 h after the onset of
reperfusion, T6) with EPO (5000 IU/kg), DPO (25 lg/kg), or
appropriate vehicle by intraperitoneal injection. Renal
function, structure, and immunohistochemistry for Bcl-2,
Bcl-XL, and Bax were analyzed. DPO or EPO at T0 significantly
abrogated renal dysfunction in IRI animals (serum creatinine
for IRI 0.1770.05 mmol/l vs DPO-IRI 0.0870.03 mmol/l vs
EPO-IRI 0.0470.01 mmol/l, P¼ 0.01). Delayed administration
of DPO or EPO (T6) also significantly abrogated subsequent
renal dysfunction (serum creatinine for IRI 0.1770.05 mmol/l
vs DPO-IRI 0.0670.01 mmol/l vs EPO-IRI 0.0370.03 mmol/l,
P¼ 0.01). There was also significantly decreased tissue injury
(apoptosis, Po0.05), decreased proapoptotic Bax, and
increased regenerative capacity, especially in the outer stripe
of the outer medulla, with DPO or EPO at T0 or T6. These
results reaffirm the potential clinical application of DPO and
EPO as novel renoprotective agents for patients at risk of
ischemic acute renal failure or after having sustained an
ischemic renal insult.
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Ischemic acute renal failure (ARF) is a common, serious
condition that culminates in patient death in over 50% of
cases.1 Numerous studies have attempted to modify the
outcome of ARF by either ameliorating renal tubular injury
(e.g. arginine–glycine–aspartate peptides, anaritide, dopa-
mine, mannitol) or promoting tubular regeneration (e.g.
hepatocyte growth factor, epidermal growth factor, insulin-
like growth factor-I).2–5 However, to date, none of these
agents has made any appreciable clinical impact on the high
mortality and morbidity rates associated with this condition.
Recently, human recombinant erythropoietin (EPO), a
widely available treatment for uremic anemia, was found to
reduce injury caused by ischemia–reperfusion (IR) of the
brain,6–11 retinal neurons,12 gut,13 liver,14 and heart.15–17 Endo-
genous EPO is known to be primarily produced by renal
cortical fibroblasts18 and it is considered that important
paracrine cytoprotective functions could occur within the
kidney, as functional EPO receptors (EPORs) are expressed
on renal tubular epithelial, mesangial, and endothelial cells.19
During the early phase of ischemic ARF, EPO expression is
virtually absent whereas EPOR expression is well main-
tained.20–23 We24 and others14,23,25–27 have demonstrated that
exogenous administration of EPO before25–27 or at23,25 the
time of bilateral renal ischemia–reperfusion injury inhibits
apoptotic cell death, enhances tubular epithelial regeneration,
and promotes renal functional recovery.
Unfortunately, in the clinical setting, most cases of
ischemic ARF are not identified until some time after the
insult has already occurred. Thus, the clinical utility of any
therapeutic agent for ARF would be greatly enhanced if
delayed administration of the drug still proved to be
renoprotective. In the setting of experimental brain injury,
EPO administration remains beneficial up to 6 h after the
onset of the inciting event.7
Whether delayed treatment with EPO or its analogues
exerts similar benefits in ischemic renal injury (IRI) is
presently unknown. Darbepoetin alfa (DPO), an erythro-
poietic agent with a serum half-life approximately three times
as long as EPO,28 might have a pharmacokinetic profile that
is clinically advantageous in ARF if it were shown to
demonstrate similar effects to that observed with EPO.
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DPO ameliorated apoptosis of porcine tubular and murine
mesangial cells induced by toxic and hypoxic stimuli.29
However, DPO has not yet been studied in in vivo models of
ischemic ARF.
The aims of the present study therefore were to determine
in an in vivo model of IRI whether (a) DPO administration
exhibited comparable renoprotection to that afforded by
EPO, and (b) delayed administration of EPO or DPO up to
6 h following IRI still ameliorated subsequent renal injury
and dysfunction. The role of pro and antiapoptotic Bcl-2
proteins in any such amelioration of renal dysfunction by
DPO or EPO was also investigated.
RESULTS
DPO and EPO both ameliorate renal histologic damage
following bilateral IRI
Examples of histopathology of IRI animals with or without
EPO or DPO are given in Figure 1a–f. Figure 1a and b is an
example of nontreated IR kidneys at 1 and 2 days,
respectively, and shows tubular epithelial cell desquamation,
primary and secondary (after loss of adhesion to basement
membrane) apoptosis, luminal casts, and necrosis. Figure
1c–f is at comparable magnification and represents IR plus
EPO (c, d) or DPO (e, f) at 1 and 2 days. EPO and DPO
treatments show lessening of the extent of renal pathology in
the outer stripe of the outer medulla (OSOM), in comparison
with IR alone. Terminal dideoxy-uridine transferase-
mediated nick end labeling (TUNEL) staining is demon-
strated in Figure 2a and b (negative control for the procedure
is shown in Figure 2c). TUNEL-positive nuclei are demon-
strated in the tubular epithelium and lumen. Luminal cells,
similar to those arrowed in Figure 1a and b, were TUNEL-
positive and apoptotic. Figure 2d–f demonstrates proliferat-
ing cell nuclear antigen (PCNA). Figure 2d represents PCNA
in control kidney sections. Figure 2e is an example of
increased PCNA with IR with and without EPO and DPO
treatments (negative control for PCNA is shown in Figure
2f). Necrosis, mainly of proximal straight segments, was seen
at around 15% of tubular epithelial cells at 24 and 48 h,
decreasing at later times to almost negligible levels at 7 days
post-IR. Details of assessment of necrosis are detailed
elsewhere.24 No amelioration of necrosis was seen with either
EPO or DPO treatments. Both the proximal straight segment
and thick ascending limb had lower levels of apoptosis with
EPO and DPO. Figure 3 summarizes histologic quantifi-
cation, and demonstrates mean7standard error of the mean
(s.e.) for counts of apoptosis and mitosis in the OSOM and
cortex, in control, IR, IR plus EPO delivered at time of
surgery (T0) and 6 h post-IR treatment (T6), and IR plus
DPO at T0 and T6. Because there were often zero counts for
control animals, the control bar is absent from some sets of
bar graphs.
Compared with control animals, rats with bilateral IRI
demonstrated significant derangements in renal histology
within 24 h, including increased tubular epithelial apoptosis
and necrosis in the OSOM (Po0.005 for apoptosis). Only
the counts for apoptosis are demonstrated. Increased
apoptosis was maintained over the period of study. Both
EPO and DPO, whether administered at T0 or T6,
significantly ameliorated the extent of injury. In many cases,
as demonstrated in Figure 3, there was a significant increase
in cell proliferation in the EPO- or DPO-treated animals
compared with the level of proliferation in the IR-alone
animals (Po0.05). Cortical proximal tubule mitotic figures
were significantly increased in EPO- or DPO-treated animals
with IRI at 1 and 2 days post-IR, compared with IR alone.
There was no pathology induced by EPO, or DPO alone and
also no significant increase in proliferation by these
treatments without IR (data not demonstrated).
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Figure 1 | Comparison of IRI injury with and without EPO and
DPO. (a) and (b) are examples of the nontreated IR kidneys at 1 and 2
days, respectively. Examples of tubular epithelial cell apoptosis are
arrowed. Epithelial cell desquamation, primary (occurring within the
epithelium) and secondary (after loss of adhesion to basement
membrane) apoptosis, luminal casts, and lytic degradation of some
cells (necrosis) are present. (c and d) are IR plus EPO at 1 and 2 days,
and (e) and (f) are IR plus DPO at 1 and 2 days, respectively. All
demonstrate fewer apoptotic cells (examples arrowed) in the tubular
epithelium, as well as fewer luminal casts. The increase in mitotic
figures (m) is seen in (c and f), and is particularly apparent in (f).
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DPO and EPO both ameliorate renal functional damage
following bilateral IRI
Both DPO and EPO administration at time of bilateral IRI in
rats significantly abrogated subsequent renal functional
impairment (Figure 4). Plasma creatinine elevations peaked
at day 2 following bilateral IRI and were significantly lower in
EPO- and DPO-treated rats compared with vehicle-treated
rats (DPO 0.0870.03 vs EPO 0.0470.01 vs vehicle 0.177
0.05 mmol/l, P¼ 0.01). DPO- and EPO-treated rats subjected
to bilateral IRI had peak plasma creatinine concentrations
(0.0870.03 vs 0.0470.01 mmol/l, respectively) that were not
significantly different from those of sham-operated controls
(whether treated with vehicle, EPO, or DPO) or each other
(P¼ 0.22). Similar results were seen for plasma urea concen-
trations, which also peaked on day 2 (DPO-treated IRI
28.6710.2 vs EPO-treated IRI 18.274.8 vs vehicle-treated
IRI 46.7711.8 vs DPO-treated sham 5.970.2 vs EPO-treated
sham 4.670.6 vs vehicle-treated sham 5.070.2 mmol/l,
Po0.01).
Administration of DPO or EPO 6 h after onset of ischemia
in rats subjected to bilateral IRI still significantly abrogated
subsequent renal functional impairment (Figure 5). Plasma
creatinine elevations peaked at day 2 and were significantly
lower in delayed DPO- and EPO-treated rats compared with
vehicle-treated rats (DPO 0.0670.01, EPO 0.0370.03 vs
vehicle 0.1770.05 mmol/l, P¼ 0.01). Delayed DPO- and
EPO-treated rats subjected to bilateral IRI had peak plasma
creatinine concentrations (0.0570.01 vs 0.0370.03 mmol/l,
respectively) that were not significantly different from those
treated with vehicle, EPO or DPO or both (P¼ 0.21). Similar
results were seen for plasma urea (delayed DPO-treated IRI
18.274.8 vs delayed EPO-treated IRI 10.573.0 vs vehicle-
treated IRI 46.7711.8 vs DPO-treated sham 5.970.2 vs
EPO-treated sham 4.670.6 vs vehicle-treated sham
5.070.2 mmol/l, Po0.01).
Hematocrit readings increased with EPO and DPO
Hematocrits gradually and significantly increased over the
7-day study period in IRI animals receiving either DPO (net
increase 9.071.5%) or EPO (8.070.8%). Similar results
were observed in sham-operated animals receiving either
DPO (11.472.1%) or EPO (8.170.4%).
Bcl-2, Bcl-XL, and Bax protein expression
Using immunohistochemistry (IHC) and Western immuno-
blot, expression of antiapoptotic Bcl-2 and Bcl-XL was not
significantly different among control and IRI kidneys with
and without EPO and DPO. Using IHC, proapoptotic Bax
expression was significantly reduced in both EPO and DPO
treatments compared with IR alone, at 2 days. Bax expression
in control kidneys was minimal (Figure 6a), except in
collecting ducts, which had moderate expression in all
kidneys. In IR kidneys, Bax was expressed mainly in proximal
and distal tubular epithelium, strongest in the proximal
straight (S3) segment and thick ascending limb in the
OSOM. The OSOM had the greatest reduced Bax expression
with EPO and DPO treatment. Kidneys from IR-treated
animals had consistently higher levels of Bax (Figure 6b)
compared with control, and EPO- and DPO-treated IR
kidneys (Figure 6c and d, respectively). Means7s.e. for IHC
a b c
fed
Figure 2 | Verification of apoptosis and mitosis. In (a and b), TUNEL-positive nuclei are demonstrated in the tubular epithelium and tubular
lumen. Note that cells similar to those arrowed as apoptotic in (a and b) are TUNEL positive. In (d and e), examples of PCNA positivity in a
control renal section (d, arrows) can be compared with the increase in the PCNA positivity in the outer medulla after IR (e, examples arrowed).
This was seen with and without EPO and DPO, but more so with the EPO and DPO treatments. Negative controls for TUNEL (c) and PCNA (f) are
demonstrated, and morphological examples of apoptosis (c) and mitosis (f) are arrowed in these photomicrographs.
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Bax expression are demonstrated in Figure 6e. Bax was
significantly increased in IR-alone animals compared with
controls. EPO and DPO treatments were associated with
decreased Bax in each instance, with significance reached for
the T6 EPO and the T0 DPO treatments (Po0.05). A similar
Bax expression pattern was also found with Western
immunoblots (Figure 7).
DISCUSSION
The present study clearly demonstrated that the administra-
tion of either DPO or EPO at the time of bilateral IRI
significantly inhibited subsequent apoptotic cell death,
enhanced tubular epithelial regeneration, minimized the
severity of renal dysfunction, and promoted more rapid renal
functional recovery. A key novel observation was that
delaying the administration of either DPO or EPO for up
to 6 h after the onset of ischemia maintained renoprotection
by these agents. This is of potential therapeutic importance,
as most cases of ischemic ARF in the clinical setting are only
diagnosed after the inciting injury has already occurred.
Indeed, our investigation did not exclude the possibility of a
significant renoprotective benefit when EPO or DPO
administration is delayed by more than 6 h after the onset
of IRI, such that further studies of more prolonged deferment
of EPO/DPO therapy following renal injury are warranted.
The finding of a protective effect of erythropoietic
compounds, even after delayed administration, is supported
by experimental brain injury studies whereby systemic
administration of recombinant human EPO before or up to
6 h after focal brain ischemia reduced cerebral injury by
approximately 50–75%.7 Similarly, treatment of rats with
EPO (5000 IU/kg) 45 min after the onset of coronary
occlusion was at least as effective at reducing the ratio of
infarct area/area at risk and the degree of myocyte apoptosis
as giving EPO 2 h before the start of ischemia.16 In a rat
model of renal IRI, a single intravenous injection of EPO
(300 U/kg) reduced glomerular dysfunction, tubular injury,
caspase activation, and apoptotic cell death, regardless of
whether the EPO was given 30 min before the commence-
ment of ischemia, 5 min before the onset of reperfusion, or
30 min following reperfusion commencement.25 Moreover,
delayed (4 h) treatment with EPO dramatically prevented the
decrease in renal expression of sodium transporters (Na-K-
ATPase and Na-K-2Cl co-transporter) associated with renal
IRI.23 In contrast, daily pretreatment with EPO (1000 IU/kg/
day subcutaneously for 3 days) afforded greater renoprotec-
tion in a mouse model of renal IRI than a single bolus
(1000 IU/kg subcutaneously) delivered at the time of
reperfusion.27 However, differences observed between the
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Figure 3 | Means7s.e. of quantified histological characteristics in
the medulla and cortex. In each case, sets of bar graphs represent
control animals (open bar), IR alone (IR, solid bar), IR plus EPO at T0
and T6 (full and open dot bars, respectively), and IR plus DPO at T0
and T6 (hatched and striped bars, respectively). In the outer stripe of
the outer medulla (outer medulla), IR induced a significant increase in
cell death (apoptosis) and mitosis (Po0.005) at all times. There was
also a small but significant increase in these parameters for IR alone
in some instances in the cortex (Po0.05). Both EPO and DPO,
whether administered at T0 or T6, significantly ameliorated the
extent of injury in the outer medulla at all times (Po0.05). In many
cases, as demonstrated for cell proliferation by #, there was a
significant increase in cell proliferation in the EPO- or DPO-treated
animals compared with the level of proliferation in the IR-alone
animals (Po0.05). Cortical proximal tubule mitotic figures were
significantly increased in EPO- or DPO-treated animals with IRI at
1 and 2 days post-IR, compared with IR alone (Po0.05).
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Figure 4 | (a) EPO and (b) DPO ameliorate renal functional
impairment following bilateral IRI. Rats were administered
intraperitoneal vehicle, EPO (5000 U/kg), or DPO (25 mg/kg) at time of
sham operation (controls) or bilateral renal artery occlusion (45 min)
followed by reperfusion. Aortic blood samples were collected for
determination of serum creatinine concentration at day 1, 2, 4, or 7
following IRI (N¼ 4 per group for each time period). *Po0.05 vs
vehicle-treated, sham-operated control. #Po0.05 vs vehicle-treated
bilateral IRI.
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two groups may have been primarily explained by the
greater cumulative dose administered to the pretreatment
group (3000 vs 1000 IU/kg) rather than the timing of
administration. Although there have been no in vivo studies
to determine the optimal renoprotective dose of erythro-
poietic agents, a previous in vitro study by our group
demonstrated that the doses of EPO needed to promote
maximal antiapoptotic and mitogenic effects in human
proximal tubule cells were quite high (200–400 IU/ml).24
Despite the fact that no toxicity has been observed in animal
models of ARF with the relatively high doses of EPO
(5000 IU/kg) and DPO (25 mg/kg) employed in our studies,
adverse sequelae in the clinical setting (e.g. thrombosis
related to hematocrit increases) cannot entirely be excluded.
In this respect, it is reassuring to note that a recent
pilot safety study for a multi-center, randomized controlled
trial of EPO in acute stroke demonstrated no adverse
effects (including no significant change in hematocrit over
30 days) from a single EPO dose of 100 000 U (approximately
1500 U/kg), despite a transient 500-fold increase in serum
EPO concentrations and a 100-fold increase in cerebrospinal
fluid EPO concentrations.30 This suggests that a similar
study of renoprotection in humans is feasible. Alternative
strategies for reducing systemic exposure might also be
possible (e.g. by direct perfusion of donor kidneys in renal
transplantation).
Our results also extend previously reported findings of a
renoprotective benefit of EPO14,23–27 by demonstrating for
the first time that DPO also ameliorated renal injury and
dysfunction in this model of ischemic ARF. One potential
mechanism for their renoprotection was decreased expression
of proapoptotic Bax, assessed using both Western immuno-
blots and IHC. There was no apparent effect in the current
model on promotion of the antiapoptotic proteins Bcl-2 and
Bcl-XL by EPO and DPO. Amongst this finding may have
represented an epiphenomenon, it is tempting to speculate
that diminished Bax may mediate the renoprotective effect of
EPO and DPO in ischemic ARF via reduction of apoptosis.
The results lend support to previous in vitro observations of a
direct antiapoptotic effect of DPO on pig tubular and mouse
mesangial cells subjected to toxic or hypoxic stimuli.29
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Figure 5 | Delayed administration of (a) EPO and (b) DPO
ameliorates renal functional impairment following bilateral IRI.
Rats were subjected to sham operation (controls) or bilateral renal
artery occlusion (45 min) followed by reperfusion (IR). Intraperitoneal
vehicle, EPO (5000 U/kg), or DPO (25 mg/kg) was administered 6 h
after the onset of ischemia. Aortic blood samples were collected for
determination of serum creatinine concentration at day 1, 2, 4, or 7
following IR (N¼ 4 per group for each time period). *Po0.05 vs
vehicle-treated, sham-operated control. #Po0.05 vs vehicle-treated
bilateral IRI.
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Figure 6 | EPO and DPO administration is associated with
diminished Bax expression in IRI kidneys. (a) and (b) are examples
of Bax expression in the control and IR alone kidneys at 2 days,
respectively and (c) and (d) are IR plus EPO, and IR plus DPO at 2 days,
respectively. A bar graph of means for Bax expression is demon-
strated for control animals vs IR animals with and without EPO and
DPO in (e). IR caused a significant increase in Bax expression index for
the IR-alone treatment (*Po0.05). and EPO and DPO treatments were
associated with decreased Bax, with significance reached for the T0
DPO and the T6 EPO treatments (**Po0.05).
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EPORs are expressed on the surfaces of a number of renal
cell types, including tubular epithelial, mesangial, and
endothelial cells.19 During the early phases of IRI, EPOR
expression is well maintained, whereas EPO expression is
markedly downregulated.20–23 In the current investigation,
renal EPOR protein expression was increased in the IR
animals, greatest at 24 h (data not demonstrated). Numerous
in vitro and in vivo studies suggest that the exogenous
administration of EPO in experimental models of brain,
heart, or kidney injury results in direct cytoprotection via a
number of mechanisms, including Janus tyrosine kinase-2
phosphorylation of inhibitor of kappaB and subsequent
nuclear factor-kappaB-dependent transcription of antiapop-
totic genes including BcL-XL, A1/Blf-1, cIAP-2, and
XIAP.9,9,15 Additional protective mechanisms that might be
activated downstream of the EPOR–Ras–mitogen-activated
protein kinase and EPOR–phosphatidyl-inosol 3-kinase
interactions include antioxidation,11 protein kinase B (Akt)
activation,31,32 direct cytotrophic effects,11 induction of heat-
shock protein-70 (HSP-70),26,33 angiogenesis,11,34,35 activa-
tion (phosphorylation) of Bcl-XL,36,37 inhibition of nitric
oxide (NO) production8,13,38 and increased mobilization and
circulation of bone marrow-derived stem cells39,40 which in
turn contribute to the regeneration of proximal tubule
epithelial cells following IRI.41
The beneficial effects of EPO on IRI and renal dysfunction
were demonstrated prior to significant increases in hemo-
globin levels, suggesting that the therapeutic effects of EPO in
IRI were independent of its hemopoietic actions. This is
supported by previous in vitro studies demonstrating direct
protective effects of EPO or DPO on tubular and mesangial
cells.24,29 Nevertheless, significant increases in hematocrits
were observed over the 7-day study period in IRI animals
receiving either DPO (net increase 9.071.5%) or EPO
(8.070.8%). Such a hemopoietic response may either be
potentially beneficial (e.g. via increased oxygen-carrying
capacity) or deleterious (e.g. via enhanced thrombotic
potential as a result of increased circulating erythrocytes
and platelet aggregation). A promising development in this
regard has been the recent demonstration that asialoerythro-
poietin, generated by total enzymatic desialylation of EPO,
provides neuroprotection without any accompanying
changes in hematocrit42 and also carbamylated EPO has
been shown to act on some of the reparative pathways of EPO
without any significant increase in hematocrit.43 Thus, it is
possible that the cytoprotective and hemopoietic actions of
EPO can be dissociated.
In conclusion, the present study demonstrated that the
administration of either DPO or EPO at the time of bilateral
IRI significantly augmented histologic and functional recov-
ery in vivo. Moreover, administration of either DPO or EPO
6 h after the onset of ischemia in the rat IRI model did not
diminish the renoprotective actions of these agents. This
raises the possibility that both DPO and EPO may have
potential clinical applications as novel renoprotective agents
for patients at risk of ischemic ARF or within a certain time
period after having sustained an ischemic renal insult.
MATERIALS AND METHODS
Bilateral IRI model
All experiments were carried out with ethics committee approval
from the University of Queensland. The IRI model was similar to
the test used by us previously.24 Briefly, mature Sprague–Dawley rats
(200–220 g) underwent either sham operation or bilateral renal
artery occlusion for 45 min followed by reperfusion. At various time
points (1, 2, 4, or 7 days) after reperfusion, rats were killed for renal
function and histology analyses (N¼ 4 per group per time point).
Rats were administered either EPO (5000 U/kg; Amgen, Melbourne,
Australia), DPO (25 mg/kg; Aranesps, Amgen, Thousand Oaks, CA,
USA), or vehicle by intraperitoneal injection, either at time of
ischemia (T0) or 6 h after reperfusion (T6). The dose of EPO was
based on that found to be maximally effective in previous studies of
acute ischemic brain injury,7,10,11 cardiac injury16 and renal injury.24
A pharmacologically equivalent amount of DPO was calculated by
dividing the EPO dose by 200.28 At the end of experiments, blood
samples were collected for determination of urea, creatinine,
sodium, chloride, lactate dehydrogenase, and hematocrit; both
kidneys were removed, bisected in an equatorial plane, fixed in
buffered formalin at 41C, and prepared routinely for histology and
IHC for two renal sections per animal.
Histology
Formalin-fixed tissue was embedded in paraffin using routine
methods, and 4 mm sections were cut onto Superfrost Plus histology
slides and stained with hematoxylin and eosin, TUNEL staining for
apoptosis, and PCNA for cell proliferation. All hematoxylin- and
eosin-stained tissue sections were viewed using light microscopy and
counted for apoptosis, necrosis, and mitosis in the tubular
epithelium of the cortex or OSOM, in 10–20 microscope fields per
section zone at  400 magnification (high-power microscopy). The
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Drug given at T = 0 h
Drug given at T = 6 h
C C+E C+D IR IR IR+E IR+E IR+D IR+D
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1d 2d 1d 2d 1d 2d
1d 2d 1d 2d 1d 2d
Cont = C = untreated IR = Ischemia/reperfusion
E = Epo
D = Dpo
1 d = 1 day
2 d = 2 days
Figure 7 | Western immunoblot of Bax. (a) Representative Western
immunoblot of renal Bax is given for nontreated, EPO and DPO
controls, IR at 24 and 48 h for the animals treated at T0 and T6. Bax
expression (top band of the doublet is 22 kDa) increased with IR, was
greatest at 24 h, and both EPO and DPO treatments were associated
with lower Bax expression than that seen in the IR animals.
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mean7s.e. for each set of counts per zone per group was then
calculated. Apoptosis was recognized by its morphological char-
acteristics:44 (i) shrunken eosinophilic cells with condensed,
marginated nuclear chromatin and intact cell membranes; (ii)
discrete apoptotic bodies comprising large, dense, pyknotic, nuclear
fragments usually surrounded by a narrow eosinophilic cytoplasmic
rim; and (iii) clusters of small apoptotic bodies (assessed as a single
apoptotic occurrence). Features of necrosis were also sought: swollen
cytoplasm with disrupted cell and organelle membranes and lytic
nuclear changes.44 Mitosis was assessed using morphological
characteristics. Similar methods for assessment of these parameters
have been published.45
Methods for biochemical verification of apoptosis and mitosis
were as follows. TUNEL: Sections were stained using a commercially
available ApopTags Peroxidase In situ Apoptosis Detection Kit
according to the manufacturer’s protocol for paraffin-embedded
sections (Chemicon, Boronia, Australia). PCNA: Sections were
deparaffinized and rehydrated, before staining with the peroxidase–
anti-peroxidase method. Nonspecific binding of peroxidase or
antibodies was blocked with 0.3% hydrogen peroxide in methanol
followed by incubation in diluted normal swine serum. The PCNA
monoclonal antibody (PC10, Oncogene Science, Dako Australia,
Botany, Australia; 1:50 dilution) was applied at 41C overnight
followed by buffer washes and the secondary antibody at a dilution
of 1 in 400 in Tris buffer, followed by the ABC-peroxidase reaction
for 30 min. The chromogen was diaminobenzidine in 0.01%
hydrogen peroxide, applied for 2–5 min. Sections were lightly
counterstained with hematoxilin and then dehydrated to xylene
and mounted in Depex.
Bcl-2 proteins – IHC and Western blot
For IHC, paraffin sections were cut at 4 mm, deparaffinized, and
rehydrated to phosphate-buffered saline, before staining with the
peroxidase–anti-peroxidase method. Primary antibodies were Bcl-2
(anti-human, mouse monoclonal; Dako Australia, Botany, Australia;
1:50 dilution) Bax, and Bcl-XL (rabbit anti-human, mouse, and rat;
Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200 dilution).
The secondary antibody was applied at a dilution of 1 in 400 in Tris
buffer. Methods then followed the PCNA IHC detailed above.
Nonspecific binding of peroxidase or antibodies was blocked with
0.3% hydrogen peroxide in methanol followed by incubation in
diluted normal swine serum. Negative controls were prepared
without primary antibody. Positive tissue control sections from
unrelated studies were included (Bcl-2 against lymphoma and rat
parotid tissue, Bax and Bcl-XL against rat gut tissue Paneth cells).
Batch staining was carried out per antibody type. Sections were
lightly counterstained with hematoxylin and then dehydrated to
xylene and mounted in Depex. Sections were viewed at  400
magnification. Intensity of expression was scored 1–4, with
1¼ background stain, 4¼most intense in the batch staining,
and two gradations between these extremes. The OSOM was
scored in each section in 5–10 fields, and in each field the
approximate percentage of tubule profiles expressing each staining
intensity was recorded. An expression index was calculated for each
of the Bcl proteins and then summarized as mean7s.e. for controls,
IR alone, IR plus EPO given at T0 or T6, and IR plus DPO given at
T0 or T6.
For Western blots, kidney tissue was disrupted in RIPA buffer
(50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.1%
sodium dodecyl sulfate, 25 mM sodium fluoride, 0.5 M ethylenedia-
mine tetra-acetic acid) containing protease and phosphatase
inhibitors (100 mg/ml phenylmethylsulfonyl chloride, 20 mg/ml
leupeptin, 20 mg/ml aprotinin, 1 mM sodium orthovanadate),
followed by centrifugation at 16 000 g for 15 min at 41C and
collection of the supernatant. Protein concentration was determined
by Bradford assay and 40 mg of total protein was electrophoresed on
a 10% sodium dodecyl sulfate–polyacrylamide gel, transferred to a
polyvinylidene difluoride membrane, and blotted routinely with the
Bax primary antibody (dilution 1:1000) and then the horseradish
peroxidase-conjugated secondary antibody, diluted (1:2000) in 5%
blotto. Protein bands were visualized using enhanced chemilumi-
nescence. Coomassie blue membrane staining or actin immunoblot
was used to verify equal protein loading of lanes.
Function analyses
Plasma sodium, potassium, creatinine, blood urea nitrogen, and
lactate dehydrogenase were measured using a modular blood
analyzer (Hitachi Australia, Milton, Australia) at the Queensland
Health Pathology Services Unit, Royal Brisbane Hospital, Australia.
Hematocrit readings were also recorded for all animals.
Statistical analysis
Results are expressed as mean7s.e. Statistical comparisons between
groups were made by analysis of variance. Pairwise multiple
comparisons were made by Fisher’s protected least-significant
differences test. P-values less than 0.05 were considered significant.
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